Clinical Trial Update: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer [Phase 3]

View source ↗

Summary

This clinical trial update notes that a Phase 3 study of Avutometinib in combination with Defactinib is underway for recurrent low-grade serous ovarian cancer a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Cancer

Drugs mentioned

• Avutometinib (VS-6766) (Avutometinib)
• defactinib (VS-6063) (defactinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Low Grade Serous Ovarian Cancer | Phase 3 | Status: RECRUITING